Italian Agency Hits Chinese Heparin Manufacturer for GMP Violations

Drug GMP Report
The Italian Medicines Agency found serious GMP violations during an Oct. 31 inspection of a heparin manufacturing facility in China and recommended that the firm be prohibited from supplying crude heparin sodium to the EU.

To View This Article:


Subscribe To Drug GMP Report

Buy This Article Now

Add this article to your cart for $40.00